ActiPatch Expands to Taiwan, Challenging Traditional Pain Management With Drug-Free Innovation

BioElectronics Corporation (OTC: BIEL), a leader in bioelectronic, drug-free pain therapy, announced the imminent commercial launch of ActiPatch in Taiwan by its appointed distributor, Aphrodite Medical Group. Aphrodite Medical Group, a well-established healthcare provider in Taiwan with a broad clinical footprint, will lead market introduction, physician engagement, and patient access initiatives across its network and affiliated channels. ActiPatch® is a US FDA-cleared, non-invasive, drug-free medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and is designed for extended wear, including during sleep - offering a practical, patient-friendly alternative to pharmaceuticals.

The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch® in Taiwan, according to Kelly Whelan, CEO of BioElectronics Corporation. Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way. The initial shipment of ActiPatch® units has been completed, positioning ActiPatch for a coordinated market launch in Q2 2026. The rollout will focus on musculoskeletal pain management, with opportunities for expansion across additional clinical applications over time.

We are pleased to bring ActiPatch® to Taiwan as part of our commitment to delivering innovative, patient-centered therapies, said Yang Pei-Hsien, Vice President, Aphrodite Medical Group. This technology aligns with the growing demand for safe, effective, and drug-free pain management options. The Taiwan launch reinforces BioElectronics’ strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. For more information about the company, visit https://www.bielcorp.com.